Litcius/Paper detail

Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study

Nick S. Nurmohamed, Didier Collard, Laurens F. Reeskamp, Yannick Kaiser, Jeffrey Kroon, Tycho R. Tromp, Bert‐Jan H. van den Born, Michiel Coppens, Alexander P. J. Vlaar, Martijn Beudel, Diederik van de Beek, Nick van Es, Patrick M. Moriarty, Sotirios Tsimikas, Erik S.G. Stroes

2021Atherosclerosis41 citationsDOIOpen Access PDF

Abstract

BACKGROUND AND AIMS: Thrombosis is a major driver of adverse outcome and mortality in patients with Coronavirus disease 2019 (COVID-19). Hypercoagulability may be related to the cytokine storm associated with COVID-19, which is mainly driven by interleukin (IL)-6. Plasma lipoprotein(a) [Lp(a)] levels increase following IL-6 upregulation and Lp(a) has anti-fibrinolytic properties. This study investigated whether Lp(a) elevation may contribute to the pro-thrombotic state hallmarking COVID-19 patients. METHODS: Lp(a), IL-6 and C-reactive protein (CRP) levels were measured in 219 hospitalized patients with COVID-19 and analyzed with linear mixed effects model. The baseline biomarkers and increases during admission were related to venous thromboembolism (VTE) incidence and clinical outcomes in a Kaplan-Meier and logistic regression analysis. RESULTS: Lp(a) levels increased significantly by a mean of 16.9 mg/dl in patients with COVID-19 during the first 21 days after admission. Serial Lp(a) measurements were available in 146 patients. In the top tertile of Lp(a) increase, 56.2% of COVID-19 patients experienced a VTE event compared to 18.4% in the lowest tertile (RR 3.06, 95% CI 1.61-5.81; p < 0.001). This association remained significant after adjusting for age, sex, IL-6 and CRP increase and number of measurements. Increases in IL-6 and CRP were not associated with VTE. Increase in Lp(a) was strongly correlated with increase in IL-6 (r = 0.44, 95% CI 0.30-0.56, p < 0.001). CONCLUSIONS: Increases in Lp(a) levels during the acute phase of COVID-19 were strongly associated with VTE incidence. The acute increase in anti-fibrinolytic Lp(a) may tilt the balance to VTE in patients hospitalized for COVID-19.

Topics & Concepts

MedicineLipoprotein(a)Internal medicineCoronavirus disease 2019 (COVID-19)Incidence (geometry)Logistic regressionGastroenterologyVenous thrombosisThrombosisInterleukin 6LipoproteinCytokineDiseaseCholesterolOpticsInfectious disease (medical specialty)PhysicsCOVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisLipoproteins and Cardiovascular Health
Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study | Litcius